GUBRA APS DK 1

At an R&D day in London, Gubra presented a strategy through 2030: its high-margin research services business is to grow by ten percent annually and the clinical portfolio expanded to eight to ten drug candidates. The focus remains on obesity; several programs are in phase 2 and the Urocortin‑2 program GUB-UCN2 will be advanced in a phase‑1/2a study with prospects for outlicensing and milestone payments. The announcements triggered share gains and underline Gubra’s ambition to create long-term value through in-house, partner- and venture-based projects. » Więcej na deraktionaer.de

The out‑licensed obesity program ABBV‑295 has entered a phase‑2 dose‑finding study, triggering a $50 million milestone payment to Gubra. In spring 2025 Gubra had already received a $350 million upfront payment from AbbVie; a further up to $1.875 billion in milestones plus tiered royalties are possible. The study will treat 360 obese or overweight adults over 52 weeks, with the primary endpoint being percent weight change at week 32. The stock has recently posted gains and, according to the chart, generated a buy signal after breaking above 400 DKK. » Więcej na deraktionaer.de

Gubra reports significant progress in biotech, CRO and ventures in H1 2026, with the CRO business returning to profit and growing sequentially by 11%. GUB‑UCN2 started Phase I/IIa, and AbbVie program ABBV‑295 achieved a median weight loss of about 10% after 12 weeks in Phase I. Management confirmed the biotech guidance for 2026 and expects a solid second half for the CRO; Ventures is reviewing initial transactions. The share fell moderately in premarket trading by about 1.27% to $390 as investors weigh pipeline progress against volatile partner payments (H1 milestones DKK 30m vs DKK 2.4bn a year earlier). » Więcej na de.investing.com